Physician profile
Brian H Gelb
NPI 1194771873
$4,330.57
in general payments reported to CMS, 2019-2025
21 companies · $1,162 in 2025
The $1,162 reported for 2025 was more than what 97% of Emergency Medical Services providers received nationally (typical 2025 total: $70.35).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $224 · 2021: $130 · 2022: $602 · 2023: $935 · 2024: $783 · 2025: $1,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,777 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,776.87 |
| Education | $103.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,300.87 | 2019-2025 | |
| Abbvie INC. | $899.84 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $408.03 | 2022-2025 | Sotyktu |
| Amgen INC. | $293.97 | 2023-2025 | Otezla, Otezla |
| Genzyme Corporation | $291.93 | 2021-2025 | |
| Ucb, INC. | $154.79 | 2019-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $144.13 | 2024-2025 | Dupixent |
| Incyte Corporation | $112.28 | 2023 | Opzelura |
| Galderma Laboratories, L.P. | $111.04 | 2019-2025 | Nemluvio |
| Celgene Corporation | $80.72 | 2019 | |
| Prugen, INC. Pharmaceuticals | $71.28 | 2019-2020 | |
| Leo Pharma INC. | $68.53 | 2025 | Anzupgo, Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.53 | 2023-2024 | Spevigo |
| Lilly USA, LLC | $60.00 | 2019-2024 | Olumiant, Taltz |
| Genentech USA, INC. | $54.46 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $53.84 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $49.74 | 2022-2025 | Nuzyra |
| Janssen Biotech, INC. | $36.99 | 2022-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $35.75 | 2020-2025 | |
| Dusa Pharmaceuticals, INC. | $19.85 | 2019 | |
| Dermavant Sciences, INC. | $15.00 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Gelb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.